Abstract
Voriconazole, a new azole antifungal agent, showed potent activity against clinical isolates of Aspergillus spp. in vitro. For A. fumigatus, the MIC range was < 0.03 to 0.5 microgram/ml and the MIC at which 90% of isolates are inhibited was 0.25 microgram/ml. In an experimental model of invasive pulmonary aspergillosis which mimics infection in humans, oral voriconazole at dosages of 30 mg/kg of body weight per day significantly delayed or prevented mortality.
Full Text
The Full Text of this article is available as a PDF (150.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barry A. L., Brown S. D. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob Agents Chemother. 1996 Aug;40(8):1948–1949. doi: 10.1128/aac.40.8.1948. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bernard E. M., Donnelly H. J., Maher M. P., Armstrong D. Use of a new bioassay to study pentamidine pharmacokinetics. J Infect Dis. 1985 Oct;152(4):750–754. doi: 10.1093/infdis/152.4.750. [DOI] [PubMed] [Google Scholar]
- Bodey G., Bueltmann B., Duguid W., Gibbs D., Hanak H., Hotchi M., Mall G., Martino P., Meunier F., Milliken S. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis. 1992 Feb;11(2):99–109. doi: 10.1007/BF01967060. [DOI] [PubMed] [Google Scholar]
- Denning D. W., Lee J. Y., Hostetler J. S., Pappas P., Kauffman C. A., Dewsnup D. H., Galgiani J. N., Graybill J. R., Sugar A. M., Catanzaro A. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med. 1994 Aug;97(2):135–144. doi: 10.1016/0002-9343(94)90023-x. [DOI] [PubMed] [Google Scholar]
- Denning D. W., Stevens D. A. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis. 1990 Nov-Dec;12(6):1147–1201. doi: 10.1093/clinids/12.6.1147. [DOI] [PubMed] [Google Scholar]
- Denning D. W. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 1996 Sep;23(3):608–615. doi: 10.1093/clinids/23.3.608. [DOI] [PubMed] [Google Scholar]
- Espinel-Ingroff A., Dawson K., Pfaller M., Anaissie E., Breslin B., Dixon D., Fothergill A., Paetznick V., Peter J., Rinaldi M. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother. 1995 Feb;39(2):314–319. doi: 10.1128/aac.39.2.314. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fisher B. D., Armstrong D., Yu B., Gold J. W. Invasive aspergillosis. Progress in early diagnosis and treatment. Am J Med. 1981 Oct;71(4):571–577. doi: 10.1016/0002-9343(81)90208-4. [DOI] [PubMed] [Google Scholar]
- George D., Miniter P., Andriole V. T. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother. 1996 Jan;40(1):86–91. doi: 10.1128/aac.40.1.86. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gerson S. L., Talbot G. H., Hurwitz S., Strom B. L., Lusk E. J., Cassileth P. A. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984 Mar;100(3):345–351. doi: 10.7326/0003-4819-100-3-345. [DOI] [PubMed] [Google Scholar]
- Grant S. M., Clissold S. P. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs. 1989 Mar;37(3):310–344. doi: 10.2165/00003495-198937030-00003. [DOI] [PubMed] [Google Scholar]
- Jorgensen J. H., Alexander G. A., Graybill J. R., Drutz D. J. Sensitive bioassay for ketoconazole in serum and cerebrospinal fluid. Antimicrob Agents Chemother. 1981 Jul;20(1):59–62. doi: 10.1128/aac.20.1.59. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kurtz M. B., Bernard E. M., Edwards F. F., Marrinan J. A., Dropinski J., Douglas C. M., Armstrong D. Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother. 1995 Aug;39(8):1784–1789. doi: 10.1128/aac.39.8.1784. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Morrison V. A., Haake R. J., Weisdorf D. J. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med. 1994 Jun;96(6):497–503. doi: 10.1016/0002-9343(94)90088-4. [DOI] [PubMed] [Google Scholar]
- Schmitt H. J., Bernard E. M., Häuser M., Armstrong D. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother. 1988 Nov;32(11):1676–1679. doi: 10.1128/aac.32.11.1676. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schmitt H. J., Edwards F., Andrade J., Niki Y., Armstrong D. Comparison of azoles against aspergilli in vitro and in an experimental model of pulmonary aspergillosis. Chemotherapy. 1992;38(2):118–126. doi: 10.1159/000238951. [DOI] [PubMed] [Google Scholar]
- Walsh T. J. Invasive pulmonary aspergillosis in patients with neoplastic diseases. Semin Respir Infect. 1990 Jun;5(2):111–122. [PubMed] [Google Scholar]